BI Invests $118 Million To Expand Production of Respimat Inhaler

By Patricia Van Arnum - DCAT Editorial Director

April 11, 2019

Boehringer Ingelheim has completed the investment of EUR 105 million ($118 million) to expand associated production operations at its sites in Dortmund and Ingelheim, Germany for its Respimat inhaler.

Respimat is a propellant-free inhaler and the basis of several inhaled respiratory medications from Boehringer Ingelheim. It produces a soft, slow-moving and long-lasting mist, which allows a high percentage of the active ingredient to be deposited deep in the lungs. The company’s new Respimat has the same features with more user-friendly elements and is reusable. The devices are available in Germany beginning in April and in additional European countries throughout the year.

Additional production space for another flexible assembly line was set up in Dortmund for the new Respimat. Of the total investment, EUR 78 million ($88 million) went toward the development and production site, and the remaining EUR 27 million ($30 million) was invested in Ingelheim for purchasing new machinery, equipment, and materials for an additional packaging line. The entire development and manufacturing process is carried out at both sites.

Source: Boehringer Ingelheim